In this online, self-learning activity:
Acne is one of the most common skin conditions treated by physicians, affecting 40 to 50 million people in the U.S. Although the disease can affect patients at any age, acne occurs most commonly during the adolescent years, with a prevalence as high as 85%. In 20% of cases, the acne is severe, resulting in permanent physical scarring as well as a mental health burden. That burden may include increased prevalence of mood disorders, psychiatric hospitalizations, school absenteeism, unemployment, and suicidality.
Acne is a multifactorial inflammatory disease affecting the hair follicles of the skin. While an understanding of acne pathogenesis is one that is continuously evolving, key pathogenic factors include follicular hyper-keratinization, microbial colonization, sebum production, and complex immune and inflammatory mechanisms. Other research suggests that neuroendocrine regulatory mechanisms, diet, and genetic and factors all may contribute to the multifactorial process of acne pathogenesis. Professional guidelines for the treatment of acne vulgaris in adolescents and adults highlight the roles of topical and systemic pharmacotherapies as well as non-pharmacologic treatment modalities, including lasers and photodynamic therapy. However, in the time since the guidelines were published, newer medications have been approved or entered late stage clinical investigation. Communicating related information to HCPs in a timely manner is a demonstrated need.
The following HCPs: dermatologists, primary care physicians, and pediatricians; nurse practitioners, physician assistants, and pharmacists who practice in dermatology and ambulatory care settings; and those who otherwise commonly care for or clinically encounter patients with acne.
Commercial Support Disclosure: This program is supported by an educational grant from Almirall, LLC.
This activity is free of charge.
Release Date: November 01, 2022 -- Expiration Date: November 01, 2024
Faculty: Charles Gropper, MD
Faculty introduction, disclosures
Introduction content: Cursory refresher and review of acne
Treatment of moderate to severe acne
· Topical therapies: Retinoids, benzoyl peroxide, androgen receptor inhibition, dapsone
· Systemic therapy: isotretinoin, antibiotics, and hormonal agents
· Recent updates in available treatment options and novel agents
· Minimizing adverse effects
Summary, conclusions, and best practice recap
By the end of the session the participant will be able to:
ACCME Activity #202345340
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
ABP MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Pediatrics' (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-22-069-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurse Practitioners (NPs): The American Academy of Nurse Practitioners accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. ScientiaCME will provide NPs who successfully complete each activity with a certificate of participation indicating that the activity was designated for AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Faculty Disclosure: Charles Gropper, MD, Clinical Associate Professor of Dermatology, Icahn School of Medicine at Mt. Sinai, has no relevant financial disclosures.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty will NOT discuss off-label uses.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Almirall.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Scratching the itch: Addressing unmet needs and updates in the pharmacotherapeutic management of atopic dermatitis (AD)
Identification and management moderate-to-severe psoriatic arthritis: stopping the disease in its tracks and meeting unmet needs
How implicit bias and culture competence shape the patient healthcare experience
Updates in psoriasis management: Contemporary practice and novel therapies